Share on StockTwits

Smith & Nephew plc (NYSE:SNN)‘s stock had its “hold” rating reaffirmed by investment analysts at Numis Securities Ltd in a note issued to investors on Tuesday.

SNN has been the subject of a number of other recent research reports. Analysts at Jefferies Group downgraded shares of Smith & Nephew plc from a “buy” rating to a “hold” rating in a research note on Tuesday. Separately, analysts at Berenberg Bank reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Tuesday, August 26th. Finally, analysts at Morgan Stanley downgraded shares of Smith & Nephew plc from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 15th. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $97.00.

Shares of Smith & Nephew plc (NYSE:SNN) traded down 0.24% on Tuesday, hitting $86.69. The stock had a trading volume of 66,031 shares. Smith & Nephew plc has a 52 week low of $58.93 and a 52 week high of $100.90. The stock’s 50-day moving average is $87.49 and its 200-day moving average is $82.69. The company has a market cap of $15.500 billion and a P/E ratio of 29.91.

Smith & Nephew plc (NYSE:SNN) last announced its earnings results on Friday, August 1st. The company reported $1.02 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.94 by $0.08. On average, analysts predict that Smith & Nephew plc will post $4.21 earnings per share for the current fiscal year.

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (NYSE:SNN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.